23 completed, 4 unknown, 2 terminated, 1 withdrawn. 20 Phase 2, 8 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 15, Unknown 3, Terminated 1, Withdrawn 1 |
| Phase 1 | 8 | Completed 6, Unknown 2 |
| Phase 3 | 6 | Completed 5, Terminated 1 |
Follow estramustine phosphate sodium: new trials by email Literature Review of estramustine phosphate sodium trials Research Report on estramustine phosphate sodium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate docetaxel, estramustine phosphate sodium, thalidomide - Prostate Cancer | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 60 | 2004-03-01 | 2012-03-15 |
| Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer estramustine phosphate sodium, paclitaxel, topotecan hydrochloride - Prostate Cancer | Phase 2 | Withdrawn | Fox Chase Cancer Center | 2003-11-01 | 2013-07-10 | |
| Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer docetaxel, estramustine phosphate sodium, ketoconazole - Prostate Cancer | Phase 3 | Completed | Eastern Cooperative Oncology Group | 2003-10-08 | 2023-06-15 | |
| Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse bicalutamide, Goserelin Acetate, docetaxel - Prostate Cancer | Phase 3 | Completed | UNICANCER | 413 | 2002-11-14 | 2023-01-18 |
| Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy recombinant interferon alfa-2b, docetaxel, estramustine phosphate sodium - Prostate Cancer | Phase 2 | Terminated | University of Medicine and Dentistry of New Jersey | 40 | 2002-11-01 | 2009-12-11 |
| Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy docetaxel, estramustine phosphate sodium, exisulind - Prostate Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 80 | 2002-11-01 | 2016-07-01 |
| Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer bicalutamide, docetaxel, doxorubicin hydrochloride - Prostate Cancer | Phase 3 | Completed | Radiation Therapy Oncology Group | 21 | 2002-10-01 | 2020-10-22 |
| Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium - Prostate Cancer | Phase 3 | Terminated | M.D. Anderson Cancer Center | 265 | 2002-04-01 | 2016-03-22 |
| S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer bicalutamide, estramustine, etoposide - Prostate Cancer | Phase 2 | Completed | SWOG Cancer Research Network | 41 | 2001-12-01 | 2013-07-16 |
| Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy docetaxel, estramustine phosphate sodium, thalidomide - Prostate Cancer | Phase 2 | Completed | Nuvance Health | 2001-09-01 | 2013-04-04 | |
| Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer estramustine phosphate sodium, ixabepilone - Prostate Cancer | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2001-07-01 | 2013-06-24 | |
| Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer estramustine phosphate sodium, docetaxel, bevacizumab - Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 72 | 2001-06-01 | 2013-06-05 |
| Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy recombinant interferon alfa, estramustine phosphate sodium, isotretinoin - Prostate Cancer | Phase 2 | Completed | Eastern Cooperative Oncology Group | 2001-04-05 | 2023-06-22 | |
| Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium - Prostate Cancer, Thromboembolism | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2000-09-01 | 2013-01-16 | |
| Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy filgrastim, carboplatin, docetaxel - Prostate Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 40 | 2000-03-01 | 2016-07-14 |
| Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer bicalutamide, estramustine phosphate sodium, etoposide - Prostate Cancer | Phase 3 | Completed | Radiation Therapy Oncology Group | 397 | 2000-01-01 | 2020-10-22 |
| Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy carboplatin, docetaxel, estramustine phosphate sodium - Prostate Cancer | Phase 1 | Completed | Dana-Farber Cancer Institute | 1999-03-01 | 2013-07-18 | |
| Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer estramustine phosphate sodium, paclitaxel - Prostate Cancer | Phase 2 | Completed | Eastern Cooperative Oncology Group | 1999-02-04 | 2023-06-15 | |
| Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer estramustine phosphate sodium, paclitaxel - Prostate Cancer | Phase 2 | Unknown | St. Barnabas Medical Center | 17 | 1998-10-01 | 2013-12-19 |
| Combination Chemotherapy in Treating Patients With Advanced Cancer estramustine phosphate sodium, paclitaxel, vinorelbine ditartrate - Leukemia, Lymphoma | Phase 1 / Phase 2 | Completed | NYU Langone Health | 1998-09-01 | 2011-03-28 |
Showing 20 of 30. Sign in to see all of them.
Prostatic Neoplasms (26) · Burkitt Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Large-Cell, Immunoblastic (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Fibrosarcoma (1) · Hodgkin Disease (1)
Eastern Cooperative Oncology Group (3) · Herbert Irving Comprehensive Cancer Center (3) · M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Alliance for Clinical Trials in Oncology (2) · Fox Chase Cancer Center (2) · NYU Langone Health (2) · Radiation Therapy Oncology Group (2) · University of New Mexico (2) · Dana-Farber Cancer Institute (1) · National Cancer Institute (NCI) (1) · National Institutes of Health Clinical Center (CC) (1) · Nuvance Health (1) · SWOG Cancer Research Network (1) · St. Barnabas Medical Center (1)
United States (28) · Canada (2) · Puerto Rico (2) · Australia (1) · France (1) · Peru (1) · South Africa (1)
Daniel P. Petrylak, MD (2) · Gary R. Hudes, MD (2) · Gregory P. Swanson, MD (2) · Randall E. Millikan, MD, PhD (2) · Robert S. DiPaola, MD (2) · William K. Kelly, DO (2) · William Oh, MD (2) · Abraham Chachoua, MD (1) · Amy D. Tiersten, MD (1) · Anthony Y. Smith, MD (1) · Arif Hussain, MD (1) · Avi S. Retter, MD (1) · David C. Smith, MD (1) · Franco M. Muggia, MD (1) · Howard M. Sandler, MD (1)
PMID 12610188, PMID 14504052, PMID 14669278, PMID 14747052, PMID 15671557, PMID 15735119, PMID 16258090, PMID 18824434, PMID 18990504, PMID 19029421, PMID 22119204, PMID 26028518, PMID 26209502, PMID 36596347
P30CA016672 (3), U10CA031946 (3), P30CA006927 (1), P30CA016087 (1), P30CA072720 (1), U10CA032102 (1), U10CA045809 (1)